Objective To evaluate the effectiveness of combination therapy with lamivudine (LAM) and hepatitis B immunoglobulin (HBIG) versus LAM monotherapy in prevention of hepatitis B virus recurrence after liver transplantation. Methods Databases including MEDLINE (Ovid), PubMed, EMbase, Cochrane Central Register of Controlled Trials (CENTRAL), CBM, VIP, and CNKI were searched up to Dec. 2008. Clinical trials including randomized controlled, non-randomized concurrent-control and case-control studies about combination therapy with HBIG and LAM versus LAM monotherapy in prevention of hepatitis B virus recurrence after liver transplantation were screened. Trial selection and data extraction were conducted by two reviewers independently. Meta-analysis was performed using RevMan 5.0.18 software. Results Eleven non-randomized concurrent-control studies involving 1 421 patients (1 035 patients in combination therapy group, and 386 patients in LAM monotherapy group) were included. The results of meta-analyses showed: Compared with LAM monotherapy group, the risks of hepatitis B virus recurrence, YMDD mutation, and death associated with HBV recurrence were significantly reduced by 73% (RR=0.27, 95%CI 0.20 to 0.37, Plt;0.000 01), 72% (RR=0.28, 95%CI 0.15 to 0.53, P=0.000 01), and 79% (RR=0.21, 95%CI 0.09 to 0.49, P=0.000 3) respectively in combination therapy group after liver transplantation; overall survival rates of both recipients and grafts in combination therapy group were similar to LAM monotherapy group (RR=1.03, 95%CI 0.95 to 1.11, P=0.51; RR=1.04, 95%CI 0.97 to 1.12, P=0.26). Conclusion Current evidence indicates that compared with LAM monotherapy, combination therapy with LAM and HBIG could reduce the risks of hepatitis B virus recurrence, YMDD mutation, and death associated with HBV recurrence after liver transplantation.
目的:研究O型RhD阳性孕妇(其丈夫为非O型)血清IgG抗-A(抗-B)抗体效价与新生儿溶血病(HDN)的关系。方法:应用微柱凝胶技术对382例O型RhD阳性孕妇进行了免疫性IgG抗A(B)抗体效价检测及对其新生儿进行HDN(①新生儿ABO、Rh系统定型;②新生儿直抗实验;③游离IgG测定;④放散实验)的检测。结果:382例O型RhD阳性孕妇中IgG抗-A(B)效价lt;64者330例(占总数86.39%),抗体效价≥64者13.61%。其中发生HDN 5例,抗-A 3例,抗-B12例,总发生率1.31%.结论:夫妇血型不合应及时检测孕妇IgG抗体,随着孕妇体内IgG抗体效价的增高,新生儿ABO溶血病的发病率也随之升高。孕妇产前应定时进行IgG抗体检测,了解效价与新生儿溶血病发病率之问的关系,对于预防新生儿溶血病极为有效。